Markets
Existing homes are more expensive than new homes
Sherwood News

Existing homes are now more expensive than new ones... That’s not normal.

This housing market is frozen, weird, and a nightmare for homebuilders.

8/27/25 7:39AM

New cars cost more than old ones. And, despite ownership cycles that are decades longer, houses tend to be the same in America, with newly built homes usually 15% to 20% more expensive than existing ones.

But, in a rare reversal of history, that’s no longer true.

Marrying two datasets from the Census Bureau and the National Association of Realtors reveals that as of July, the median sales price of new homes, at $403,800, was lower than the $422,400 median price of existing homes nationally.

Harder, better, cheaper, newer?

Exactly why this is happening is complex. The short answer is that there’s simply way too many newly completed homes. As of July, the inventory of unsold new homes on the market would take more than nine months to clear, the highest in 15 years excluding the pandemic, compared to 4.6 months of supply for existing homes.

To attract buyers in such a market, homebuilders are adding discounts to new home deals, like mortgage rate “buydowns” of about 5% on average, in a bid to trim their overflowing inventory — even if it hurts their margins. In fact, a record 38% of builders said they cut home prices in July, per the National Association of Home Builders.

Existing homeowners, however, aren’t feeling as flexible on price, probably because for most of them, moving would involve reentering the mortgage market and giving up the cushy rate they might have secured during the pandemic. With no incentive to move out, America’s existing home sales hit their slowest pace in nearly three decades last year, with homeowners experiencing the strongest “mortgage lock-in effect” since the 1980s.

With slipping demand across the industry, homebuilders have also been building smaller homes to cater to cost-conscious moderate-income buyers — the typical size of a new home built nowadays is some 13% smaller than from 2015s peak, per the Census Bureau.

More Markets

See all Markets
markets
Luke Kawa
9/5/25

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.